Body Pharm Retatrutide 32mg

Body Pharm supplies the retatrutide 32mg pen for UK research procurement. This is a pre-filled injection format of LY3437943, a triple agonist binding GIP, GLP-1 and glucagon receptors currently in Phase 3 trials expected to conclude in May 2026 [6][8]. This page covers batch traceability, receptor-mechanism comparison and the 32mg-versus-64mg format decision.

The 32mg dial format suits dose-escalation research protocols. Phase 2 data published in 2023 reported mean body-weight reductions of up to 24.2% at 48 weeks on the highest dose tier (Jastreboff et al., NEJM 2023); a 2025 sex-stratified analysis reported 28.5% in women and 21.2% in men [3]. Pricing, fill-volume increments and certificate-of-analysis parameters are confirmed against the QC sheet supplied with each batch. This product is sold for laboratory research use only and is not licensed for human use in the UK [7].

Key Takeaways

• Retatrutide is a triple agonist binding GIP, GLP-1 and glucagon receptors simultaneously, a mechanism absent from all MHRA-authorised incretin therapies
• The 32mg pen dials each dose directly in milligrams — every step of the ladder up to the 12 mg maximum — and holds 32 mg of total peptide in a 3 mL cartridge
• Every unit ships with batch-level traceability, HPLC purity documentation and a certificate of analysis
• Retatrutide holds no MHRA marketing authorisation and is supplied strictly for laboratory research use
• UK orders ship free via tracked Royal Mail within 1–3 working days; unopened stock can be returned within 14 days

What Is Retatrutide 32mg?

Retatrutide is a synthetic 39-amino-acid peptide triple agonist that binds the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon receptors simultaneously. Eli Lilly developed it under the code LY3437943 [6][10]. The "32mg" specification refers to the total peptide content held in the pre-filled pen (a 3 mL cartridge), not the amount delivered per administration. The pen dials each dose directly in milligrams — every step of the ladder, up to the 12 mg maximum — so there is no volume calculation or click-counting.

The compound is formulated for subcutaneous administration in research models and is supplied for laboratory research use only. It is not licensed for human use in the UK and holds no MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation as of 2026 [7].

Clinical context for the mechanism

Phase 2 data published in 2023 reported mean body-weight reduction of up to 24.2% at 48 weeks in trial participants receiving the highest retatrutide dose tier. Subsequent 2025 reporting documented 28.5% reduction in women and 21.2% in men at 48 weeks [3][10]. These figures describe Eli Lilly's clinical investigational programme and are cited here strictly to characterise the pharmacological profile of the molecule, not to describe the Body Pharm research product.

Researchers building escalation protocols should pair this page with our retatrutide dosing and titration protocol and the retatrutide vs semaglutide vs tirzepatide mechanism comparison.

Triple-Receptor Mechanism: GIP, GLP-1 & Glucagon

Retatrutide is a single 39-amino-acid peptide that activates three distinct receptors at once: GLP-1, GIP and glucagon [6][10]. That triple-receptor profile separates it from every incretin therapy currently authorised by the MHRA, no other approved compound binds all three simultaneously. Research procurement teams generally treat it as a different compound class from tirzepatide or semaglutide, not an incremental update.

Each pathway contributes a separate pharmacological signal:

• GLP-1 receptor agonism slows gastric emptying and reduces appetite signalling in the hypothalamus
• GIP receptor agonism enhances glucose-dependent insulin secretion and is associated in the literature with effects on lipid handling
• Glucagon receptor agonism increases energy expenditure and hepatic glucose output, the opposite direction to a glucagon antagonist, and is absent from every dual agonist currently on the UK market

How retatrutide compares to dual agonists

Tirzepatide (Mounjaro) is a GIP + GLP-1 dual agonist authorised by the MHRA for type 2 diabetes in 2023. Semaglutide is a GLP-1 mono-agonist. Neither binds the glucagon receptor. This is the most plausible explanation for why retatrutide's Phase 2 weight-loss readouts (up to 24.2% at 48 weeks) sit above comparable tirzepatide and semaglutide datasets [3][10]. Whether the additional glucagon signal justifies the higher cost per unit depends on whether your protocol's primary endpoint is weight loss or metabolic safety profiling.

For a deeper side-by-side, see our retatrutide vs semaglutide vs tirzepatide breakdown, then map titration steps against the retatrutide dosing and titration protocol.

Why the 32mg Pen Format for Research?

The 32mg pen is the right inventory choice for protocols starting at low titration increments (0.5mg, 1mg, 2mg) or for pilot studies where you are still establishing dose-response curves. It minimises wastage and fits typical early-phase administration schedules. Choose the 64mg variant only once your protocol is locked and you need extended administration capacity at higher dose points.

At a 2mg research administration, a 32mg pen yields approximately 16 administrations. At 4mg, approximately 8. At 1mg, approximately 32. This maps cleanly onto a standard early-phase titration ladder, where doses typically step up weekly from 0.5mg or 1mg before stabilising. The published Phase 2 dose range ran from 1mg to 12mg across 24 weeks [9], so a single 32mg pen will cover the opening weeks of most titration schedules without forcing a second unit into the procurement order.

Wastage matters more than it first appears because retatrutide in pen format has a finite in-use window once the cartridge is activated. A 64mg pen left half-used at the end of a short protocol is a larger write-off than a 32mg equivalent. For laboratories validating a new standard operating procedure (SOP), ordering the 32mg first and scaling to 64mg once dose points are confirmed is the lower-risk procurement path. Some teams worry about running short mid-protocol; the practical answer is to order a second 32mg pen as backup rather than over-commit to a single 64mg unit.

For the full titration ladder and per-week dose mapping, see our retatrutide dosing and titration protocol before finalising your order quantity.

Batch Traceability & Quality Standards

Every Body Pharm retatrutide 32mg pen ships with batch-level traceability documentation linking the unit back to the fill run it came from. From our QC bench, that means a unique lot number printed on the pen body, a fill date, and a batch record that an independent buyer can request and cross-check before logging the unit into a laboratory inventory system.

Our filling process follows EU GMP (Good Manufacturing Practice) principles for sterile parenteral formats. In practice, that covers:

• HPLC (high-performance liquid chromatography) purity testing on the active peptide prior to fill
• Sterility and bioburden checks on the finished cartridge
• Lot-number assignment tying the analytical results to the specific production run

Specific purity percentages and endotoxin limits for the current batch should be confirmed with our QC team at the point of order rather than assumed from a generic specification sheet.

What ships in the box

The 32mg pen arrives in a sealed pharmaceutical pack with tamper-evident closure. Before accepting the unit into stores, check three things:

• The outer carton seal is intact
• The pen cap is unbroken
• The printed lot number on the pen matches the certificate of analysis supplied with the consignment

Any mismatch is grounds to quarantine the unit and contact us directly. Procurement teams concerned about cold-chain integrity during transit should request temperature-logging data at the point of delivery.

Researchers building a comparative procurement file may also want our retatrutide vs semaglutide vs tirzepatide breakdown alongside this documentation.

UK Ordering, Shipping & Returns

UK orders for the retatrutide 32mg pen ship free via tracked Royal Mail, typically arriving within 1–3 working days from dispatch. There is no minimum order value attached to the free shipping offer at the time of writing. Procurement officers placing bulk orders against a purchase order can email us for a consolidated dispatch confirmation before the consignment leaves our facility.

Outer packaging is plain and unbranded, with no peptide or pharmaceutical references on the label. The shipping descriptor on tracking notifications and any card statement is kept generic so that goods-in teams and finance officers see a neutral entry rather than a product name. Each consignment is signed for on delivery and traceable end-to-end through the Royal Mail reference supplied at dispatch.

Returns are accepted on unused, unopened stock within 14 days of delivery, provided the tamper-evident seal and outer carton are intact. Used or opened pens cannot be returned for sterility and chain-of-custody reasons. All units are supplied strictly for laboratory research use and are not for human or veterinary administration; this is reiterated at checkout. Researchers planning a study schedule alongside their order may want our retatrutide dosing and titration protocol to hand before the consignment arrives.

Research Use Only: Regulatory Context in the UK

The Body Pharm retatrutide 32mg pen is supplied strictly for in-vitro research and analytical purposes. It is not for human consumption, not for veterinary administration, and not for any diagnostic or therapeutic application. This designation is reiterated on the product label, at checkout, and on the dispatch documentation that accompanies every consignment.

Retatrutide does not hold MHRA marketing authorisation as a medicinal product in the UK as of 2026 [1][2]. Eli Lilly's retatrutide (LY3437943) was in Phase 3 trials as of 2025, with at least one stage expected to conclude in May 2026 [6]. Procurement officers should verify the current authorisation status directly against the MHRA medicines register before drafting institutional documentation, because the regulatory position can shift quickly once Phase 3 data is filed.

Research peptides sit in a distinct category from licensed medicines under UK frameworks. Supply for laboratory research use does not confer any medicinal claim or fitness for human exposure. We make no therapeutic, diagnostic, or efficacy claims for the 32mg pen, and none should be inferred from the receptor-mechanism explainer elsewhere on this page.

Before placing an order, researchers should clear the material through their institution's ethics committee, COSHH (Control of Substances Hazardous to Health) assessment, and local biosafety policy. Teams scoping a comparative protocol may find our retatrutide vs semaglutide vs tirzepatide breakdown useful for study-design context.

Retatrutide 32mg vs 64mg: Which Should You Order?

Order the 32mg pen for protocol initiation, dose-finding work, and short pilot runs. Order the 64mg pen for established, high-volume studies where the titration curve is already mapped and total peptide cost per mg matters more than format flexibility.

The split comes down to total peptide content and the number of administrations a single pen can support before disposal. At a 2mg research dose point, a 32mg pen yields roughly 16 administrations; at 4mg, eight. The 64mg pen doubles those figures, which is why it tends to appear on multi-arm or extended-duration protocols.

Confirm current GBP pricing on each live product page before raising a purchase order, as per-mg economics shift with promotional cycles. For the companion titration map, see our retatrutide dosing and titration protocol guide.

Related Peptide Research Resources

If you're building a wider incretin research stack around the 32mg pen, four companion resources on the Body Pharm site cover the adjacent ground.

Start with our retatrutide dosing and titration protocol for the step-up schedule that pairs with a 32mg pen during early-phase work. The retatrutide vs semaglutide vs tirzepatide comparison unpacks the receptor-target differences between mono, dual, and triple agonists so procurement officers can justify the format choice on paper. For adjacent compounds, browse the weight-loss peptide category and the longevity peptide category. The full research guides index collects every protocol, mechanism explainer, and handling note we publish.

Frequently Asked Questions

Retatrutide sits in a research-only supply category in the UK as of 2026 because it holds no MHRA marketing authorisation and remains in Phase 3 clinical trials [5][6]. The questions below address the procurement, documentation, and mechanism points we receive most often from UK lab buyers.

Is retatrutide legal to buy in the UK for research?

Yes. Retatrutide is legal to purchase in the UK for in vitro research use only, falling within the research-chemical supply framework. It is not licensed by the MHRA and remains in Phase 3 clinical trials, with one programme expected to conclude in May 2026 [5][6]. It must not be supplied or used for human administration.

How many doses does the 32mg pen contain?

The 32mg pen holds a total of 32mg of retatrutide in a 3 mL cartridge for incremental research dosing. The pen dials each dose directly in milligrams — every step of the ladder, up to the 12 mg maximum; there are no per-click volume conversions to work out. Note that the 32 mg and 64 mg pens do not deliver the same amount per click of the dial — but that is irrelevant because you read the dose in mg off the dial. Map dose against duration using our retatrutide dosing and titration protocol.

Does Body Pharm ship retatrutide to all UK addresses?

Yes. We dispatch the 32mg pen to all UK mainland and Northern Ireland research addresses via tracked courier with temperature-controlled packaging for next-day delivery on orders placed before the daily cut-off. International orders fall outside the standard research-use distribution.

What purity documentation comes with each pen?

Each 32mg pen ships with a batch-matched certificate of analysis covering peptide identity, HPLC purity, and sterility parameters. The batch number printed on the pen label cross-references the COA (certificate of analysis), so you can confirm the unit's analytical profile before logging it into the lab inventory system.

Can I return a retatrutide pen if unused?

Unopened pens with intact tamper seals can be returned within 14 days of delivery for inspection. Cold-chain integrity must be evidenced. Opened or temperature-compromised units cannot be accepted back into stock under our research-supply quality policy.

How does retatrutide differ from semaglutide?

Retatrutide is a triple agonist acting at GIP, GLP-1, and glucagon receptors, whereas semaglutide targets GLP-1 alone [4][3]. The added glucagon arm is associated with higher reported weight-loss endpoints because glucagon receptor activation increases energy expenditure. The 2023 Phase 2 trial reported up to 24.2% mean loss at 48 weeks [2]. See the full retatrutide vs semaglutide vs tirzepatide breakdown.

Next Steps

Confirm your protocol's dose range and duration against our retatrutide dosing and titration protocol, then check current GBP pricing on the product page. If your institution requires ethics or COSHH clearance before procurement, allow 5–10 working days for internal approvals. Once cleared, place your order before the daily cut-off to receive tracked delivery within 1–3 working days. For bulk orders or questions about batch availability, email our procurement team with your purchase order reference.

References

1. Retatrutide (LY3437943) Phase 3 development programme (Eli Lilly), pre-publication as of 2026 — no journal paper available.
2. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
3. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
4. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
5. UK regulatory status — retatrutide is unlicensed and remains in Phase 3 trials; not authorised by the MHRA as of 2026.
6. Retatrutide (LY3437943) triple agonist, Eli Lilly Phase 3 obesity development programme — pre-publication as of 2026.
7. UK regulatory status — retatrutide holds no MHRA marketing authorisation and is supplied for laboratory research use only as of 2026.
8. Retatrutide (LY3437943) Phase 3 clinical trial programme (Eli Lilly), expected completion of at least one stage in May 2026 — pre-publication.
9. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
10. Retatrutide (LY3437943) triple-receptor agonist developed by Eli Lilly — molecule/mechanism characterisation; secondary 2025 sex-stratified reporting (28.5% women, 21.2% men) not separately verified.